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Abstract
Cyproheptadine prevention of the neuropsychiatric adverse effects of an antiretroviral regimen including efa-
virenz has been evaluated in a randomized clinical trial. Twenty-five patients (16 males and 9 females with
mean – SD ages of 36 – 9 years) in a cyproheptadine group, and 26 patients (17 males and 9 females with
mean – SD ages of 34 – 7 years) in a control group completed the trial. Sexual contact and injection drug use were
the main routs of HIV infection in both groups. The patients’ neuropsychiatric adverse effects were evaluated
based on the Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale, Positive and Negative Syn-
drome Scale, Beck Depression Scale, Pittsburgh Sleep Quality Inventory, Positive and Negative Suicide Ideation,
and Somatization Subscale of Symptom Checklist 90 at baseline and 4 weeks after treatment. Cyproheptadine
significantly decreased the scores of Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale, Positive
and Negative Syndrome Scale, Beck Depression Scale, Pittsburgh Sleep Quality Inventory, Positive and Negative
Suicide Ideation of the patients after 4 weeks in comparison with control group. All of the scores increased in
control group following antiretroviral therapy. Although short duration of the patients’ follow-up was a major
limitation of the study, the results of the study showed that cyprohepradine is effective in prevention of
depression, anxiety, hallucination, aggressive behaviors, emotional withdrawal, poor rapport, poor impulse
control, active social avoidance, suicidal ideation, and improved sleep quality of HIV-positive patients after
initiation of antiretroviral therapy including efavirenz.
Introduction
Suppression of human immune deficiency virus (HIV)replication and decrease in morbidity and mortality of
HIV-positive patients have been documented following an-
tiretroviral therapy (ART), but this regimen has numerous
adverse drug reactions (ADR).1 Based on the severity of the
ADR, modification or ending of treatment may be required.1
Efavirenz is a potent non-nucleoside reverse transcriptase
inhibitor (NNRTI) with favorable pharmacokinetic charac-
teristics and few known ADR. These properties make it as a
first-line drug in combination with other ART for treatment of
HIV infection.2,3 More than 50% of patients who take efavir-
enz will experience neuropsychiatric ADR of this drug.4,5
Discontinuation of efavirenz due to its neuropsychiatric ADR
has been reported in 2–13% of patients.6–9 Interruption of
efavirenz can promote viral resistance to this drug and other
NNRTIs.8 The neuropsychiatric ADR usually are mild to
moderate and include dizziness, headache, nightmares, ab-
normal dreams, mild cognitive difficulty, sleep disturbance
(somnolence, insomnia), impaired concentration, and fa-
tigue.1,10,11 Severe adverse effects have been reported in less
than 2% of patients and include suicidal depression (one per
1000), hallucinations, delusions, paranoia, anxiety, agitation,
aggressive behavior, mania, emotional lability, catatonia,
melancholia, and psychosis.4,6,10–13 These adverse effects of-
ten start after the first dose, peak at 14 days, and commonly
disappear after onemonth of efavirenz treatment.8,9,14 Several
psychotropic categories including antidepressants (citalo-
pram, sertraline, mirtazepine, reboxetine, venlafaxine), anti-
psychotics (olanzapine, risperidone, amisulpride, sulpiride),
mood stabilizers (valproate, lamotrigine), and anxiolytics
(oxazepam, lorazepam, temazepam, zopiclone) are proposed
for relieving the neuropsychiatric ADR of efavirenz.15,16 The
Departments of 1Clinical Pharmacy, Faculty of Pharmacy, 3Psychiatry and Psychology Research Center, Rozbeh Hospital, 4Department of
Infectious Diseases, Iranian Research Center of HIV/AIDS, and 5Brain and Spinal Cord Injury Research Center, Imam Khomeini Hospital
Complex, Tehran University of Medical Sciences, Tehran, Iran.
2Department of Clinical Pharmacy, Faculty of Pharmacy, Kerman University of Medical Sciences, Tehran, Iran.
AIDS PATIENT CARE and STDs
Volume 27, Number 3, 2013
ª Mary Ann Liebert, Inc.
DOI: 10.1089/apc.2012.0410
146
interaction between psychotropic drugs and antiretroviral
medications is a considerable problem.14,16 Selection of an
appropriate psychotropic agent with a broad spectrum ac-
tivity and minimum drug interaction with ART is a challenge
in the prevention or treatment of ART-associated neuropsy-
chiatric ADR.
Cyproheptadine is an available, cheap, and relatively safe
5-hydroxytryptamine 2 (5-HT2) receptor antagonist. Its af-
finity to interact with dopamine, histamine, and adrenergic
and muscarinic receptors is relatively high.17 The 5-HT 2 an-
tagonists are beneficial in the treatment of psychiatric disorders
such as schizophrenia, anxiety, and depression.18–20 It does not
have significant drug interaction via cytochrome P450 with
ART (Lexi-Comp 2012, Micromedex Version 1514, 2010).21 It is
also used for treatment of recurrent and post-traumatic night-
mares and prevention of vascular types of headache, especially
migraine attack.22–26 Cyproheptadine is a hypnotic drug that
can used for sleep induction and also to improve sleep quantity
and quality.27 Common side effects of cyproheptadine are in-
creased appetite and weight gain28 that can be beneficial in
HIV-positive individuals with decreased appetite and weight
loss.29,30 Based on this evidence, cyproheptadine could be a
useful agent in prevention of neuropsychiatric ADR of efavir-
enz with beneficial effects on appetite and weight in HIV-
positive patients. In this study, the effects of cyproheptadine
in prevention of neuropsychiatric ADR of ART including
efavirenz has been evaluated in a randomized clinical trial.
Methods
This double-blind, randomized clinical trial was conducted
in the HIV clinic of Imam Khomeini Hospital in Tehran, Iran,
during 2011–2012. The clinical trial was registered at the Ira-
nian Registry of Clinical Trials; its identity number is
IRCT201103106026N. Patients with documented HIV infec-
tion (based on ELISA and Western Blot tests), aged between
18 and 65 years, and who were candidates for initiating ART
including efavirenz were included in the trial. Patients with
previous history of ART treatment including efavirenz,
pregnancy, use of other medications that may affect the pa-
tients’ mood, and history of major psychiatric disorders were
excluded from the study. Sixty-four patients were screened,
but 13 patients (8 patients in cyproheptadine group and 5
patients in placebo group) were excluded (Fig. 1). Fifty-one
patients completed this trial. Stages of HIV infection was
determined according to the 1993 revised classification of
Centers for Disease Control and Prevention (CDC) defini-
tion.31 The included patients were divided into two groups
(cyproheptadine and placebo) using block randomization.
Twenty-five patients were in the cyproheptadine group, and
26 patients were in the placebo group. The trial was approved
by the ethical committee of Tehran University of Medical
Sciences; each participant signed an informed written con-
sent. Cyproheptadine was administered in a dose of 8mg per
day for 1 week, and 12mg per day for the other 3 weeks in the
cyproheptadine group; placebo patients received the same
dose and frequency in control group. The patients were fol-
lowed for 4 weeks. Neuropsychiatric ADR were evaluated on
the day 0 and 28 of treatment by the following scales: Ha-
milton Depression Rating scale (HDRS), Hamilton Anxiety
Rating Scale (HARS), Positive and Negative Syndrome Scale
(PANSS), Beck Depression Inventory-2nd Edition (BDI-II),
Pittsburgh Sleep Quality Inventory (PSQI), Positive and Ne-
gative Suicide Ideation (PANSI), and Somatization subscale of
Symptom Checklist 90 (SCL 90). The expert interviewer
completed HDRS, HARS, and PANSS questionnaires. HDRS,
a validated Persian version,32 was used to assess the patients’
depression. The HDRS is a 17-item scale and rates from 0 (not
present) to 4 (severe) for each item.33 HARS, a validated
Persian version,32 was used for evaluation of the patients’
anxiety status. The HARS includes 14 parameters and scores
from 0 (not present) to 4 (severe) for each item.34 PANSS, a
validated Persian version35–37 was used to assess the patients’
positive symptoms such as hallucinatory behavior and hos-
tility. This questionnaire includes 30 items and scores from 1
(absent) to 7 (extreme) for each item. Seven items for positive
symptoms, 7 items for negative symptoms, and 16 items for
general symptoms.38,39 BDI-II, a validated Persian version,40
was applied for evaluation of depression by patients. This
self-report questionnaire includes 21 items and scores from 0
(absent) to 3 (severe) for each item.41 Positive and Negative
Suicide Ideation is a self- report questionnaire that includes 14
items and scores from 0 to 4 for each item. PANSI has two
subscales: Positive Suicidal Ideation with 6 items and Nega-
tive Suicidal Ideation with 8 items.42 The reliability of these
two subscales was estimated using Cronbach’s alpha reli-
ability coefficient. This coefficient was 0.83 for Positive Sui-
cidal Ideation and 0.94 for Negative Suicidal Ideation. PSQI, a
validated Persian version,43 used to evaluate sleep quality
during the study period. PSQI is a self-measured, 7-compo-
nent questionnaire (subjective sleep quality, sleep latency,
sleep duration, habitual sleep efficiency, sleep disturbances,
use of sleeping medications, and daytime dysfunction). Pa-
tients with a total score greater than 5 are classified as poor
sleepers.44 Somatization subscale of SCL-90, a validated Per-
sian version,45,46 was used for assessing physiological factors.
Somatization dimension of SCL-90 represents physical mor-
bidity. This self-reported questionnaire includes 12 items. This
subscale represents distress in different systems such as car-
diovascular, gastrointestinal, respiratory, and autonomic
systems, and rated from 0 (none) to 4 (extreme)47 for each
item. Since increased appetite and sleep are common side
effects of cyproheptadine, the sleep and appetite items of BDI-
II and daytime dysfunction item of PSQI were deleted and the
scores of these two questionnaires were re-analyzed.
The statistical package of social science (SPSS) version 16
was used for all analyses. The patients’ demographic and
laboratory data were evaluated by descriptive analysis. Two-
tailed t-test and chi-square (or Fisher’s exact test) was used to
compare demographic, laboratory, and clinical data of the
patients. We used two-way repeated measured analysis of
variance to compute the effect of independent factors (cy-
proheptadine and efavirenz therapy) on the emerging neu-
ropsychiatric adverse effects and changes in the patients’
weight. Paired sample t-tests were used to calculate the
changes in scores of the scales in each group. We considered
p values less than 0.05 as statistically significant.
Results
From the included patients, 33 (64.7%) were male, and 18
(35.3%) were female. The most common opportunistic infec-
tion and concomitant disease in the patients were candidiasis
(9.8 %) and hepatitis C infection (25.5 %). The major routes of
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HIV transmission were sexual contact (39.2 %) and intrave-
nous drug use (31.4 %). Most of the patients were in stage A
(70.6 %) of HIV infection. Demographic characteristics of the
patients have been summarized in Table 1. There was no
significant difference regarding the patients’ age, sex, route of
HIV transmission, time between HIV infection to AIDS, job,
education, stage of HIV infection, concomitant diseases, op-
portunistic infections, and concomitant medications between
cyproheptadine and control groups.
Themean – SD of the patients’ laboratory data are shown in
Table 2. There was no significant difference in patients’ he-
matologic parameters, CD4 count, liver enzyme tests, renal
function tests, lipid profile, and blood sugar at baseline and 4
weeks later between cyproheptadine and control groups.
Severities of the patients’ neuropsychiatric problems are
listed in Table 3. Based on HDRS, HARS, BDI-II, and BDI-II
without sleep and appetite items scales, the patients’ neuro-
psychiatric status were categorized as normal, minimal, mild,
moderate, or severe. Most of the patients were in a mild,
normal, and minimal category of HDRS, HARS, and BDI-II,
respectively. There was not any significant difference in fre-
quency of these scores between the groups at baseline and
after 4 weeks except for HDRS score in the cyproheptadine
group after 4 weeks ( p= 0.015).
Based on the two-way repeated measure analysis of vari-
ance, mean – SD of HDRS was decreased from 14.68 – 7.32 to
8.00 – 7.84 in the cyproheptadine group that was significantly
( p = 0.0001) different from the control group after 4 weeks.
Also, the mean – SD of HARS decreased from 11.12 – 6.29 to
5.36 – 6.17 following 4 weeks of cyproheptadine therapy that
was significantly ( p = 0.0001) different from the control
group. Positive ( p = 0.002), negative ( p = 0.0001), and general
( p = 0.001) symptoms of the patients were also changed sig-
nificantly in the cyproheptadine group compared with con-
trols. The patients’ BDI-II ( p = 0.004), PANSI ( p = 0.047), PSQI
( p = 0.0001) scores were decreased significantly from
21.24 – 13.51, 14.20 – 11.56, and 7.64 – 4.19 to 18.32 – 15.67,
12.04 – 12.08, and 5.76 – 3.82, respectively, after 4 weeks
treatment with cyproheptadine. Although the patients so-
matization status improved based on the SCL-90 scores, these
changes were not significant in all patients. None of these
scales changed significantly in the control group after 4 weeks
in comparison with the cyproheptadine group.
The mean – SD of the scales in each group at baseline and
after 4 weeks of intervention are shown in Table 4.
Discussion
BothHIV infection andART, including efavirenz, nevirapin,
zidovudine, lamivudine, abacavir, and didanosine, have some
neuropsychiatric adverse effects.1,16,48 HIV infection causes
psychiatric complications ranging from depression to mania
FIG. 1. Consort flowchart.
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or mean – SD p Valuea
Sex
Male 16 (64%) 17 (65.4%) 0.918
Female 9 (36%) 9 (34.6%)
Age 36– 9 34 – 7 0.415
Time between HIV infection up to AIDS (months) 21 – 30 12– 23 0.215
Education
Illiterate 2 (8.0%) 1 (3.8%) 0.311
Elementary 3 (12.0%) 6 (23.1%)
Guidance school 7 (28.0%) 2 (7.7%)
High school 10 (40.0%) 12 (46.2%)
More than diploma 3 (12.0%) 5 (19.2%)
Transmission
IV drug injection 9 (36.0%) 7 (26.9%) 0.692
Sex 11 (44.0%) 9 (34.6%)
Needle 1 (4.0%) 2 (7.7%)
IV drug injection and sex 2 (8.0%) 5 (19.2%)
Unknown 2 (8.0%) 2 (7.7%)
Blood 0 (0.0%) 1 (3.8%)
Job
Self-employed 10 (40.0%) 15 (57.7%) 0.209
House-hold 5 (20.0%) 5 (19.2%)
Employee 1 (4.0%) 2 (7.7%)
Student 1 (4.0%) 1 (3.8%)
Taxi driver 4 (16.0%) 0 (0.0%)
Unemployed 3 (12.0%) 0 (0.0%)
Engineer 0 (0.0%) 1 (3.8%)
Medical staff 1 (4.0%) 2 (7.7%)
Opportunistic infections
TB 0 (0.0%) 1(3.8%) 0.289
CMV 0 (0.0%) 2 (7.7%)
Candidiasis 3 (12.0%) 2 (7.7%)
None 20 (80.0%) 20 (76.9%)
Zoster 2 (8.0%) 0 (0.0%)
TB and candidiasis 0 (0.0%) 1 (3.8%)
Concomitant diseases
Diabetes 0 (0.0%) 1 (3.8%) 0.320
Depression 1 (4.0%) 0 (0.0%)
HCV 7 (28.0%) 4 (15.4%)
GI disease 2 (8.0%) 0 (0.0%)
None 14 (56.0%) 20 (76.9%)
HBV and HCV 1 (4.0%) 1 (3.8%)
State of marriage
Single 10 (40.0%) 8 (30.8%) 0.779
Married 12 (48.0%) 14 (53.8%)
Divorced 3 (12.0%) 4 (15.4%)
Stage of HIV infection
A 19 (76.0%) 17 (65.4%) 0.068
B 5 (20.0%) 2 (7.7%)
C 0 (0.0%) 4 (15.4%)
Concomitant medication
Cotrimaxazole 16 (64.0%) 12 (46.2%) 0.200
Gancyclovir 0 (0.0%) 2 (7.7%) 0. 255
Benzodiazepine 4 (16.0%) 2 (7.7%) 0.315
SSRI 1 (4.0%) 0 (0.0%) 0. 490
Fluconazole 3 (12.0%) 2 (7.7%) 0.481
INH, B6 2 (8.0%) 4 (15.4%) 0.353
PPI 1 (4.0%) 1 (3.8%) 0.745
INH,RIF, PYZ, 0 (0.0%) 2 (7.7%) 0.255
ETM, B6 Acyclovir 2 (8.0%) 0 (0.0%) 0.235
Insulin 0 (0.0%) 1 (3.8%) 0. 510
B6, Vitamin B6; CMV, cytomegalovirus; ETM, ethambutol; GI, gastrointestinal; HBV, hepatitis B virus; HCV, hepatitis C virus; INH,
isoniazid; IV, intravenous; PYZ, pyrazinamide; RIF, rifampin; SSRI, selective serotonin reuptake inhibitor; TB, tuberculosis.
aChi square or Fisher’s exact test.
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and psychosis.1 Neuropsychiatric ADR of efavirenz are com-
mon4,5 and cause up to 13% of ART discontinuation.6–9 It must
be considered that patient-reported symptoms as a whole in
efavirenz-based ART regimens are less than other regimens.51
Psychotropic medications are used to relieve mild to
moderate neuropsychiatric adverse effects.16 Cessation of
efavirenz therapy may be needed in severe cases.1 Peyrierea
and colleagues10 reported three cases of efavirenz-induced
CNS toxicity. One of these cases stopped efavirenz because
of serious reactions. Other cases with efavirenz were man-
aged with dose reduction. The authors proposed that ad-
ministration of efavirenz regardless of patient’s weight can
cause high plasma concentration in low weight and patients
with hypoalbuminemia. High serum concentration of free
efavirenz will advance its neuropsychiatric adverse ef-
fects.10 Gutierrez-Valencia et al.5 used stepped-dose therapy
of efavirenz over 2 weeks and concluded that this approach
can reduce the severity and frequency of efavirenz-related
neuropsychiatric adverse effects while its efficacy is main-
tained.5 However, the efficacy and safety of dose escalation
have not been established, and the manufacturer of efavir-
enz has discouraged this approach due to potential risk
Table 2. Laboratory Data of Patients
Variable (mean –SD) Cyproheptadine Control p Valuea
WBC 5160.461– 1665.98 5502.73– 2116.50 0.549
Neutrophils (percent) 57.82– 10.06 59.03– 9.28 0.687
CD4 count 148.57– 117.51 164.09– 121.23 0.665
Hemoglobin 12.98– 2.49 12.68– 1.84 0.644
Hematocrit 39.23– 6.25 38.15– 5.04 0.529
Platelets 205317.74– 114829.61 206981.82– 123155.68 0.963
Urea 23.00– 7.64 27.00– 10.12 0.156
Creatinine 1.25 – 1.33 0.99 – 0.25 0.382
ALT 44.91– 50.86 31.91– 27.24 0.294
AST 51.74– 67.17 32.86– 25.02 0.222
ALP 8973.09– 42078.45 207.18– 86.64 0.334
ESR 23.13– 20.71 29.31– 32.48 0.516
Cholesterol 139.32– 30.23 140.06– 32.52 0.943
Triglyceride 101.89– 43.42 162.39– 118.21 0.044
HDL 31.16– 11.17 30.11– 8.53 0.752
LDL 79.10– 23.13 78.11– 27.03 0.905
FBS 92.40– 14.45 112.60– 78.22 0.263
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ESR, erythrocyte sedimentation rate; FBS,
fasting blood sugar; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SD, standard deviation; WBC, white blood cell.
aTwo tailed t- test.
Table 3. Severities of Patient Neuropsychiatric Status at Baseline and after 4 Weeks
Group (base)
Number (percent)
Group (after 4 weeks)
Number (percent)







Normal (0–7) 3 (12.0%) 8 (30.8%) 15 (60.0%) 5 (19.2%) 0.372 0.015
Mild (8–13) 9 (36.0%) 10 (38.5%) 6 (24.0%) 9 (34.6%)
Moderate (14–18) 4 (16.0%) 4 (15.4%) 2 (8.0%) 9 (34.6%)
Severe (19–22) 5 (20.0%) 2 (7.7%) 0 (0.0%) 2 (7.7%)
Very Severe (‡ 23) 4 (16.0%) 2 (7.7%) 2 (8.0%) 1 (3.8%)
Hamilton Anxiety
Rating Scale
Normal (0–13) 16 (64.0%) 24 (92.3%) 22 (88.0%) 21(80.8%) 0.095 0.445
Mild (14–17) 7 (28.0%) 2 (7.7%) 2 (8.0%) 4 (15.4%)
Moderate (18–24) 1 (4.0%) 0(0.0%) 1(4.0%) 0 (0.0%)




Minimal l (0–13) 9 (36.0%) 11 (42.3%) 13 (52.0%) 9 (34.6%) 0.059 0.537
Mild (14–19) 6 (24.0%) 2 (7.7%) 1 (4.0%) 3 (11.5%)
Moderate (20–28) 4 (16.0%) 11(42.3%) 4 (16.0%) 6 (23.1%)






Minimal l (0–13) 10 (40.0%) 12 (46.2%) 14 (56.0%) 11(42.3%) 0.619 0.516
Mild (14–19) 5 (20.0%) 5 (19.2%) 3 (12.0%) 4 (15.4%)
Moderate (20–28) 5 (20.0%) 7 (26.9%) 1 (4.0%) 4 (15.4%)
Severe (29–63) 5 (20.0%) 2 (7.7%) 7 (28.0%) 7 (26.9%)
aBased on Chi-square or Fisher-exact test analysis.
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of resistance.2 We have not found any effective and safe
intervention for prevention of neuropsychiatric adverse ef-
fects of ART in our literature review. Appropriate preven-
tion of these ADR can minimize ART discontinuation
and improve patients’ adherence to therapy. In the lim-
ited studies, cyproheptadine showed beneficial effects
on the treatment of acute and chronic schizophrenia,49–51
anxiety,19 depression,52 and recurrent and post-traumatic
nightmares.22,23,53 It can also improve quantity and quality
of sleep.27 Common side effects of cyproheptadine (appetite
improvement and weight gain)28 can be useful in HIV-
positive patients.
In the present study, cyproheptadine significantly de-
creased the scores of 6 scales (HDRS, HARS, PANSS, PANSI,
BDI-II, and PSQI) after 4 weeks. All of these scores increased
in the control (placebo) group following 4weeks, and increase
in HARS, HDRS, and PANSS were statistically significant.
Greenway and others52 reported antidepressant effects of
cyproheptadine in 6 patients with major depression in a
double-blind, crossover trial. The HDRS scores of 4 patients
decreased after 8 weeks treatment with cyproheptadine.52
Akhondzadeh and colleagues50 reported the results of a ran-
domized double-blind placebo controlled study of cypro-
heptadine in 30 patients with chronic schizophrenia. Patients
were randomly treated with 30mg haloperidol and 24mg
cyproheptadine per day or 30mg haloperidol daily plus pla-
cebo for 8 weeks. PANSS scores were higher in the placebo
group in comparisonwith the cyproheptadine group at weeks
4, 6, and 8.50 Silver et al.54 also investigated the effect of cy-
proheptadine augmentation therapy with haloperidol in 10
patients with chronic schizophrenia. The authors concluded
that cyproheptadine can be effective on ameliorating both
positive and negative symptoms in the patients.54 Our finding
showed that cyproheptadine can prevent depression, anxiety,
positive symptoms (hallucination and aggressive behaviors),
negative symptoms (emotional withdrawal and poor rap-
port), and general symptoms (poor impulse control and active
social avoidance) of HIV-positive patients who starting ART
including efavirenz.
The sleep quality, which was evaluated by PSQI, signifi-
cantly improved in the cyproheptadine group. Tokunaga
et al.27 evaluated the effects of some H1-antagonists, in-
cluding oral cyproheptadine, on the sleep-wake cycle in
sleep-disturbed rats in comparisonwith oral nitazepam in an
experimental study. In this study, cyproheptadine decreased
the total waking time and increased the total nonrapid eye
movement (non-REM) sleep time, slowwave sleep, and delta
activity.27 The score of PSQI increased in placebo group but
was not statistically significant. Sleep disturbance is a com-
mon neuropsychiatric adverse effect of efavirenz.1,10,55
When sleep and appetite items of BDI-II and daytime dys-
function of PSQI were excluded, the results of repeated an-
alyses did not differ significantly than the BDI-II and PSQI
scales. Although there are not enough data regarding cor-
relation between efavirenz and risk of suicide,8 this study
showed that the mean of suicidal ideation scores increased
Table 4. Comparison of Weight and Neuropsychiatric Characteristics of the Patients at Baseline
and Following Cyproheptadine (A) or Placebo (B) Intervention
Baseline After 4 weeks p Value p Value
Variable Group mean –SD mean– SD within groupsa between groupsb
Weight (kg) A 65.02– 12.32 66.34– 12.45 0.452 0.297
B 67.73– 13.17 68.38– 13.00 0.569
HDRS A 14.68– 7.32 8.00 – 7.84 0.072 0.0001
B 11.15– 6.37 12.65– 5.67 0.018
HARS A 11.12– 6.29 5.36 – 6.17 0.008 0.0001
B 6.92 – 4.46 8.50 – 4.83 0.048
PSS A 9.08 – 1.78 8.00 – 1.38 0.255 0.002
B 8.54 – 1.58 9.38 – 2.08 0.008
NSS A 9.16 – 2.19 7.76 – 1.33 0.013 0.0001
B 7.85 – 1.35 8.96 – 2.37 0.031
GSS A 25.16– 4.39 20.72– 4.23 0.082 0.001
B 23.11– 3.83 23.77– 5.66 0.035
BDI-II A 21.24– 13.51 18.32– 15.67 0.140 0.004
B 16.31– 9.73 20.77– 12.35 0.537
BDI_II Without
questions 16 and 18
A 19.08– 12.54 16.00– 14.44 0.150 0.003
B 14.61– 9.05 18.69– 11.83 0.469
Suicidal ideation A 14.20– 11.56 12.04– 12.08 0.044 0.047
B 8.77 – 6.68 10.81– 7.49 0.662
Somatization A 14.48– 7.73 15.76– 10.37 0.014 0.224
Subscale of SCL 90 B 9.31 – 6.81 13.69– 9.44 0.460
PSQI A 7.64 – 4.19 5.76 – 3.82 0.006 0.0001
B 4.50 – 3.58 7.04 – 4.62 0.288
PSQI A 7.32 – 4.03 5.36 – 3.68 0.009 0.0001
Without question 7 B 4.42 – 3.57 6.69 – 4.42 0.249
BDI-II, Beck Depression Inventory-2nd Edition; GSS, General Symptoms Scale; HARS, Hamilton Anxiety Rating Scale; HDRS, Hamilton
Depression Rating Scale; NSS, Negative Symptoms Scale; PSQI, Pittsburg Sleep Quality Inventory; PSS, Positive Symptoms Scale; PSS,
Positive Symptoms Scale; SD, Standard Deviation; SCL 90, Symptom Check List 90.
aPaired t-test; btwo way repeated measure analysis of variance.
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after 4 weeks in placebo group, although it was not signifi-
cant. The mean of PANSI was decreased in the cypro-
heptadine group significantly. This finding showed that
cyproheptadine is effective in prevention of suicidal ideation
following initiation of ART including efavirenz. Cypro-
heptadine was not effective in preventing or decreasing the
physical morbidity in various systems of the patients. The
mean of somatization subscale of SCL-90 was increased
significantly within the cyproheptadine group and insignif-
icantly in the control group, but these changes was not sig-
nificant in comparison between groups. The common side
effects of ART are nausea, vomiting, headache, dizziness,
malaise, myalgia, and peripheral neurologic complications
such as neuropathic pain, neuropathic weakness, and de-
nervation syndromes.14,56 These side effects increased so-
matization subscale of SCL-90 scores.
Themean of patients’ weight was increased after 4weeks in
both groups, but it was not significant within and between
groups. Sense of well-being and improvement in general
condition of HIV-positive patients following ART, can in-
crease patients’ appetite and weight.
Stiel et al.,57 Daviss et al.,28 Homnick et al.,58 Epifanio
et al.,59 and Rerksuppaphol et al.60 investigated the effect of
cyproheptadine on weight gain in healthy people, ADHD
individuals, patients with cystic fibrosis, and malnourished
children, respectively. They concluded that cyproheptadine
can increase weight in these populations. Cyproheptadine did
not cause significant weight gain in our HIV-positive patients,
which may be due to small sample size and short duration of
intervention in this study.
The main route of HIV transmission in the Iranian popu-
lation is injection drug use.61–63 In the present study, the most
common route of HIV transmission in the patients was sexual
contact. We excluded IDUpatients whowere under treatment
with methadone because of efavirenz–methadone interaction.
Efavirenz can increase metabolism of methadone and results
in occurrence of withdrawal symptoms that may be mistaken
with efavirenz neuropsychiatric adverse effects.5
Although the results of this study showed that cyprohep-
tadine is effective in prevention of neuropsychiatric adverse
effects of ART including efavirenz, the study had some limi-
tations. Small sample size and short duration of the patients’
follow-up were major limitations of the study. Seven different
questionnaires were used for evaluation of the patients’ neu-
ropsychiatric status. In average, about 1 h was needed for
each patient’s interview and complementation of the ques-
tionnaires that was boring for some patients. It may have
influenced the accuracy of the patients’ responses. The results
of this study must be confirmed in future clinical trials with
sufficient sample size and long term follow-up. As neuro-
psychiatric effects of EFV often resolve spontaneously within
4 weeks, additional studies at shorter (2 week) and longer
(several month) intervals with cyproheptadine might be tried.
This is first study that has evaluated the efficacy of an in-
tervention (cyproheptadine) in prevention of ART-induced
neuropsychiatric adverse effects. The results showed that
cyprohepradine is effective in prevention of anxiety, depres-
sion, hallucination, aggressive behaviors, emotional with-
drawal, poor rapport, poor impulse control, active social
avoidance, suicidal ideation, and improved sleep quality of
HIV-positive patients following initiation of ART including
efavirenz.
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